Innovative Topical Therapy for Otic Eczema

An innovative topical treatment for psoriasis and atopic dermatitis has recently received patent approval from the Spanish Ministry of Industry, Trade, and Tourism. This topical treatment Psorisbye, presented in the form of a lotion, includes a combination of clobetasol, papaverine hydrochloride, spironolactone, a milk-peptide complex, and propylene glycol. A 56-year-old female presented to our outpatient clinic with bilateral otic eczema. The patient had no significant past medical history and primarily complained of intense pruritus in the lesions. The patient was advised to use our recently patented lotion, Psorisbye, once daily for 7 days. Two days after beginning the treatment, the patient experienced significant relief from itching sensations. By the 8th day, during an examination at the outpatient clinic, a notable improvement in the scaled lesions was observed. While the preliminary results exhibited by Psorisbye in the context of this specific case are indeed promising, the imperative to establish its efficacy and reliability necessitates the initiation of further investigations characterized by more expansive sample sizes and prolonged follow-up periods.

Introduction

Eczematous external otitis is a prevalent chronic condition that can profoundly affect the quality of life of those afflicted, causing persistent discomfort, itching, and ultimately, sleep deprivation [1].

Topical corticosteroids in the form of otic solutions have been a longstanding treatment option for otic eczema for many years [1]–[3]. Otic eczema tends to be chronic or recurrent despite treatment with topical corticosteroids [4].

The Spanish Ministry of Industry, Trade, and Tourism has recently granted patent approval (Invention patent reference number 202030824) for a ground-breaking topical treatment designed for psoriasis. This innovative treatment, presented in the form of a lotion, includes a combination of clobetasol, papaverine hydrochloride, spironolactone, a milk-peptide complex, and propylene glycol [5], [6].

We showcase a case of otic eczema that was treated using our newly patented lotion, Psorisbye.

Case Report

A 56-year-old female presented with bilateral otic eczema. The patient had no significant past medical history and primarily complained of intense pruritus in the lesions.

During the examination, crusting and scaling were observed on the front sides of both ears. Additionally, a few abrasions from scratching were identified.

She received the diagnosis nearly 40 years ago, and utilizing corticosteroid creams since 2016 and moisturizers for addressing dry skin.

The patient was advised to use our recently patented lotion, Psorisbye, once daily for a duration of 7 days.

Two days after beginning the treatment, the patient experienced significant relief from itching sensations. By the 8^th day, during an examination at the outpatient clinic, a notable improvement in the scaled lesions was observed.

Figs. 1 and 2 illustrate the right ear of the patient before and after the application of Psorisbye, with an 8-day interval between the images.

Fig. 1. Right ear of a 56-year-old female patient with otic eczema before treatment.

Fig. 2. Right ear of a 56-year-old female patient with otic eczema after treatment with Psorisbye for 1 week.

Discussion and Conclusions

We have herein showcased a case of otic eczema successfully treated with our innovative lotion. Notably, substantial improvement was evident after only 2 days of topical application of Psorisbye.

The effectiveness of the innovative topical treatment was evident in the significant improvement observed, as evidenced by the disappearance of pruritus sensations and a notable reduction in the signs of otic eczema.

The outstanding outcomes observed in this case can be attributed to the synergistic effects and well-balanced dosages of the medications incorporated in Psorisbye [5], [6]. In our case report, we did not observe any adverse reactions or interactions among the different molecules in the new topical treatment.

The outcomes of our case involving otic eczema align with our previously published case reports on Psorisbye, which have recently showcased the effectiveness of the new foaming lotion in managing moderate psoriasis in the short term [5], [6].

While the preliminary results exhibited by Psorisbye in the context of this specific case are indeed promising, the imperative to establish its efficacy and reliability necessitates the initiation of further investigations characterized by more expansive sample sizes and prolonged follow-up periods. Conducting such comprehensive studies will not only serve to validate the preliminary findings articulated in our current case report but also contribute to a more robust understanding of the potential long-term effectiveness and safety profile of the aforementioned topical treatment.